Quarterlies Top 5: Cokal and MSL were today’s top performers
Link copied to
The deadline for companies to submit reports is the last business day of the first month after the prior quarter which is this Friday – if they don’t, they risk suspension and consequential panic and anger from shareholders.
As the week progresses and the market announcements page becomes increasingly flooded with lodgements, Stockhead will sort through the best performers so you don’t have to.
Shares gained another 20% this morning as it reminded shareholders that it was close to its goal.
During the quarter the company employed staff to manage activities in preparation for mining and begun work on repair of the access road to the tenement.
This company has software aimed at sport and hospitality venues – such as MPower Stadiums which helps stadium operators manage workforces and see analytics in real time.
MSL recorded its fourth straight quarter of positive operational cash flows generating $2 million in net operating cash from $8.1 million in cash receipts.
It closed the quarter with a cash balance of $5.4 million and tips an earnings result of at least $2.5 million, exclusive of government support subsidies.
The company reminded shareholders of key contract wins in FY21 including with RAC Arena Perth and event management company ASM Global but subsequent to the quarter’s end a 3-year deal with Manchester City to deploy its solutions across the club’s football grounds.
The rare earths producer reported sales revenue of $185.9 million (up from $110 million last quarter) and sales receipts of $192 million in a result the company claimed was a record.
However its REO production fell from 4,463 tonnes to 3,778 tonnes and NdPr production was only slightly higher from 1,359 tonnes to 1,393 tonnes.
The company says demand for its products was strong with demand from the automotive and FCC sectors back to pre-COVID levels despite a brief decline in NdPr prices and the global shortage of semi-conductors.
The result came despite the COVID-19 situation in Malaysia requiring the company to limit staff on site to 40%.
During the quarter the company also begun preliminary site works and submitted its final Environmental Review Document (ERD) for its Kalgoorlie project and submitted Phase 1 engineering and design work for its proposed Heavy Rare Earths facility in the US.
The lung imaging medtech listed almost a year ago and while off its all time highs is more than double its IPO price.
Highlights during the quarter included a US$600,000 purchase order from the University of Michigan and initiating deployment of proceeds from its grant awards earlier this year to its development and commercialisation activities.
4D Medical also begun its first clinical trial for its Ventilation-Perfusion (VQ) product at the University of Miami in May and hopes to apply for FDA approval for this product next year.
For more information on 4D’s update, read this morning’s ASX biotech wrap here.
The bookmaking company reported $8.9 million in cash receipts in the last quarter.
It claims this was not just its strongest quarter to date but 71% higher than the March quarter in FY21 and 272% higher than the June quarter in FY20.
It closed the quarter with over $120 million in cash and while it didn’t manage to get a hold of Tabcorp, it did complete the acquisition of betting tech business Sportech and is moving to snap up Form Cruncher and Swopstakes.
It also witnessed the legalisation of fixed odds wagering in New Jersey – a key market for the company.